# A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

> **NCT06318676** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 26 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Mezigdomide

## Key facts

- **NCT ID:** NCT06318676
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-21
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318676, "A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06318676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*